本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 16 日 (二)股东大会召开的地点：江西省南昌市新建区招贤 1 路江中药谷会议室 证券代码：600750 证券简称：江中药业 公告编号：2025-028 江中药业股份有限公司 2024年年度股东大会决议公告 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 562 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 344,161,234 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数 | 54.7140 | | 的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由董事长刘为权先生主持，采取现场投票与网络投票相结合的表决方式。 表决方式符合《公司法》及《公司章程》的有关规定。 (五)公司董事、监事和董事 ...

国浩律师（上海）事务所 关于江中药业股份有限公司 国浩律师（上海）事务所 法律意见书 本法律意见书依据国家有关法律、法规的规定而出具。 本所律师同意将本法律意见书作为公司本次股东大会的必备文件公告，并依 法对本所出具的法律意见承担责任。 本所律师已经对与出具法律意见书有关的所有文件材料及证言进行审查判 断，并据此出具法律意见如下： 一、本次股东大会的召集、召开程序 公司召开本次股东大会，董事会于 2025 年 4 月 26 日以公告方式通知各股 东。公司发布的公告载明了会议的时间、现场会议地点、会议审议的议题，说明 国浩律师（上海）事务所 法律意见书 2024 年年度股东大会的法律意见书 致：江中药业股份有限公司 江中药业股份有限公司（以下简称"公司"）2024 年年度股东大会（以下简称 "本次股东大会"）现场会议定于 2025 年 5 月 16 日下午 14:00 在江西省南昌市新 建区招贤 1 路江中药谷会议室召开，国浩律师（上海）事务所（以下简称"本所"） 接受公司的委托，指派本所律师出席会议，并依据《中华人民共和国证券法》、 《中华人民共和国公司法》和《江中药业股份有限公司章程》（以下简称《公司 章程 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600750 证券简称：江中药业 公告编号：2025-029 江中药业股份有限公司 第十届监事会第五次会议决议公告 江中药业股份有限公司（以下简称"公司"）第十届监事会第五次会议于 2025 年 5 月 16 日在公司会议室以现场结合视频方式召开，会议通知于 2025 年 5 月 9 日以书面形式发出，应参会监事 3 人，实到 3 人。会议召集召开符合 《公司法》和《公司章程》的有关规定。 会议由公司监事会主席周娇女士主持，经与会监事认真讨论，审议通过以 下议案： 一、关于江中药业第二期限制性股票激励计划向激励对象首次授予限制性 股票的议案 表决情况：3 票同意，0 票反对，0 票弃权。通过本议案。 监事会认为，董事会确定的首次授予日符合《管理办法》和公司《第二期 限制性股票激励计划》有关授予日的相关规定。公司和激励对象均未发生不得 授予或获授限制性股票的情形，且公司层面业绩及个人层面绩效均考核达标， 公司本次激励计划规定的授予条件已经成就。 首次授予激励对象符合 ...

江中药业股份有限公司（以下简称"公司"）第十届监事会第五次会议于 2025 年 5 月 16 日在公司会议室召开，审议通过了《关于江中药业第二期限制性 股票激励计划向激励对象首次授予限制性股票的议案》。 江中药业股份有限公司监事会 关于公司第二期限制性股票激励计划首次授予 激励对象名单（授予日）的核查意见 公司监事会依据《中华人民共和国公司法》（以下简称《公司法》）、《中 华人民共和国证券法》（以下简称《证券法》）、《上市公司股权激励管理办法》 （以下简称《管理办法》）等有关规定，对公司《第二期限制性股票激励计划》 （以下简称"本次激励计划"）首次授予激励对象名单（授予日）进行了核查， 发表核查意见如下： （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； 1、公司本次激励计划确定的首次授予激励对象及其获授限制性股票的情况 与公司 2024 年年度股东大会审议通过的激励计划一致。 （5）法律法规规定不得参与上市公司股权激励的； 2、本次获授限制性股票的激励对象为公司（含下属子公司）任职的董事、 高级管理人员、中层管理人员、科研骨干人员及业务骨干人员。 3、本次获授权益的激励对象不存在《管理办法》 ...

Core Viewpoint - The food and beverage industry is increasingly adopting the term "super" to enhance product appeal, moving beyond traditional taste and health narratives to attract consumers [4][9]. Group 1: Trends in Food and Beverage Industry - The term "super" is prevalent in the industry, with products being marketed as "superfoods" and "super ingredients" to stand out in a crowded market [4][9]. - There is a growing trend of blending human food and pet food, with both industries focusing on health and simplicity [12]. - Technological advancements in food production are leading to a "restorative" approach, where natural flavors are enhanced through innovative methods [15][20]. Group 2: Consumer Preferences and Innovations - The rise of "plant-based" beverages and foods is evident, with companies exploring various plant resources for new product development [41][45]. - The beverage industry is shifting towards consumer sovereignty, where brands must adapt to consumer demands rather than dictate what consumers should buy [51][52]. - There is a notable increase in the variety of sweeteners and flavorings available, allowing for more personalized beverage options [18][19]. Group 3: Health and Wellness Focus - The industry is emphasizing health by reducing sugar and salt content, with companies developing complex solutions for flavor enhancement [66][67]. - The concept of "natural health" is being integrated into everyday products, with brands promoting drinks that replace traditional water with health-focused alternatives [79][80]. - The market is witnessing a dichotomy where health-oriented products coexist with indulgent options, reflecting diverse consumer preferences [73][76].

Core Insights - The food and beverage industry is increasingly focusing on "super" products, moving beyond traditional taste evaluations to emphasize health and functionality [3][5][46] - The trend of "super" extends across demographics, with products tailored for adults, children, and specific gender needs [5][6] - Innovations in food technology are leading to a more diverse and refined product offering, including natural sweeteners and plant-based alternatives [9][13][39] Industry Trends - The concept of "superfoods" is prevalent, with various ingredients being marketed as health-enhancing, such as "medicinal foods" and unique plant extracts [3][46] - The integration of food and pet industries is notable, with similar health trends appearing in both sectors [6][7] - The rise of "XX waters" and plant-based beverages indicates a shift towards healthier hydration options, with numerous new products emerging [27][29] Technological Advancements - Advances in food technology are focusing on "restoration" of natural flavors, with the use of yeast extracts and other natural ingredients to enhance taste without added sugars [9][13] - The development of new sweeteners, such as "tagatose," offers lower-calorie options while maintaining sweetness, reflecting a trend towards healthier alternatives [13][39] - Companies are increasingly utilizing a formulaic approach to create new beverage products, combining various plant and herbal ingredients to appeal to health-conscious consumers [30][32] Consumer Behavior - The shift towards health-oriented products is evident, with consumers increasingly seeking functional benefits from their food and beverages rather than just taste [46] - The food industry is adapting to consumer preferences, moving from a production-driven model to a consumer-driven one, where brands must respond to specific health needs [29][39] - Despite the health trends, indulgent products like high-calorie snacks and desserts continue to thrive, indicating a complex consumer landscape [44][45]

Core Viewpoint - In Q1 2025, the company reported a revenue of 1.184 billion yuan, a year-on-year decrease of 7.03%, while achieving a net profit attributable to shareholders of 285 million yuan, an increase of 5.91% [1] Group 1: Financial Performance - The company's Q1 2025 revenue breakdown includes 885 million yuan from the OTC segment (down 12.12% YoY), 187 million yuan from the prescription drug segment (up 23.68% YoY), and 111 million yuan from the health segment (up 0.59% YoY) [1] - The gross profit margin and net profit margin for Q1 2025 were 68.21% and 24.06%, respectively, reflecting increases of 1.20 percentage points and 2.94 percentage points YoY [1] Group 2: Cost Management - The company's expense ratios for sales, management, R&D, and financial costs in Q1 2025 were 33.80%, 4.51%, 2.28%, and -1.49%, showing changes of -1.79, +1.31, -0.07, and +0.20 percentage points YoY, respectively [2] Group 3: Future Outlook - The company is expected to achieve revenues of 4.9 billion yuan, 5.542 billion yuan, and 6.224 billion yuan from 2025 to 2027, with year-on-year growth rates of 10%, 13%, and 12% [2] - The projected net profits attributable to shareholders for the same period are 890 million yuan, 1.028 billion yuan, and 1.172 billion yuan, with growth rates of 13%, 16%, and 14% [2] - The company maintains a "buy" rating with projected PE valuations of 16, 14, and 12 times for 2025, 2026, and 2027, respectively [2]

Group 1 - The "Jiangxi sector" achieved nearly 1.08 trillion yuan in total operating revenue in 2024, ranking tenth among 31 provinces and cities in China [1] - Jiangxi listed companies distributed a total dividend of nearly 10.4 billion yuan in 2024, with a dividend payout ratio of approximately 77%, ranking eighth nationwide [1][3] - Jiangxi Copper (600362) reported over 520 billion yuan in operating revenue for 2024, with a net profit of 6.962 billion yuan, marking a year-on-year increase of 7.03% [1] Group 2 - JinkoSolar (688223) topped the A-share photovoltaic industry with an annual operating revenue of 92.471 billion yuan, achieving a global module shipment of 92.87 GW, a year-on-year growth of 18.28% [1] - The company maintained its position as the global leader in module shipments for the sixth consecutive year, with N-type module shipments accounting for 88% of total shipments in 2024 [1] Group 3 - Major infrastructure projects like the Gan-Shen High-speed Railway and Gan-Yue Canal are transforming Jiangxi from an "inland hinterland" to an "open frontier" [2] - Jiangxi Copper is expanding internationally with new offices in South America and Southeast Asia, while JinkoSolar is establishing a new battery and module factory in Saudi Arabia [2] - Other companies like Funeng Technology (688567) and Nipe Mining (300818) are also advancing their international strategies, indicating a trend of "Jiangxi manufacturing" integrating into the global supply chain [2] Group 4 - Jiangxi listed companies are focusing on refining their core businesses while actively implementing the "1269" action plan to upgrade traditional industries and foster emerging sectors [3] - In 2024, Jiangxi Copper allocated 2.417 billion yuan for cash dividends, with several other companies also distributing over 500 million yuan in dividends [3] - The overall dividend distribution of nearly 10.4 billion yuan reflects a strong commitment to shareholder returns and social responsibility among Jiangxi enterprises [3] Group 5 - As the "14th Five-Year Plan" approaches its conclusion, Jiangxi listed companies are showing promising new developments, with traditional industry giants and emerging players competing in the capital market [4] - The formation of a trillion-level non-ferrous metal industry cluster and a photovoltaic new energy base is expected to enhance the national ranking of the "Jiangxi sector" in the next five years [4]

Group 1 - The core viewpoint of the article is that Jiangzhong Pharmaceutical Co., Ltd. has publicly announced the list of individuals who will be granted restricted stock under its second phase incentive plan, confirming that the selection process complies with relevant regulations and guidelines [1][3]. - The company conducted an internal public notice from April 29, 2025, to May 8, 2025, regarding the names and positions of 168 individuals selected as incentive recipients, with no objections raised during the public notice period [1]. - The supervisory board of the company has verified that the selected incentive recipients meet the eligibility criteria set forth in the relevant laws, regulations, and the company's incentive plan, confirming that there are no disqualifying circumstances [3]. Group 2 - The supervisory board concluded that the individuals listed as incentive recipients are legally and effectively qualified to receive restricted stock, adhering to the conditions outlined in the guiding documents and the company's articles of association [3]. - The incentive recipients do not include independent directors, supervisors, or shareholders holding more than 5% of the company's shares, ensuring compliance with the regulations [3]. - The announcement serves to affirm the legitimacy of the incentive plan's implementation and the qualifications of the selected individuals [1][3].

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. is focused on high-quality development, emphasizing innovation, governance, and sustainable practices to enhance its core competitiveness and shareholder value. Group 1: Company Governance and Strategy - The company aims to create a world-class enterprise by enhancing the quality of listed companies and deepening the construction of the industrial chain [4][6][16] - The board of directors has implemented a modern governance structure, holding 4 shareholder meetings and 11 board meetings in 2024, approving 17 and 65 proposals respectively [6][17] - The company emphasizes the integration of party leadership with business development, enhancing political awareness and theoretical learning [4][9] Group 2: Financial Performance and Shareholder Returns - In 2024, the company distributed a total cash dividend of 755.10 million yuan, maintaining a stable and continuous dividend policy [14][26] - The company reported a stable revenue scale with improved profitability, despite industry policy impacts [4][9] - The company has maintained a cash dividend payout ratio exceeding 60% since its listing [14] Group 3: Innovation and R&D - The company is committed to increasing R&D investment intensity and promoting digital transformation, with a focus on developing new quality productivity [9][10] - The company has received national recognition for its R&D projects, including a second-class award for technological progress [9][10] - The company aims to enhance its product matrix and optimize business models to strengthen its market position in OTC and prescription drugs [9][18] Group 4: Risk Management and Compliance - The board has established a compliance management system, appointing a chief compliance officer to oversee risk management [8][19] - The company conducts regular internal control evaluations and has received positive audit reports regarding its financial and operational compliance [24][25][27] - The company emphasizes the importance of risk prevention and compliance culture among its employees [19][20] Group 5: ESG and Sustainable Development - The company has integrated ESG principles into its governance framework, achieving an A rating in ESG assessments [12][20] - The company actively discloses its social responsibility reports and has been recognized for its commitment to sustainable practices [12][20] - The board has established a dedicated committee to oversee ESG initiatives, enhancing the company's sustainable development capabilities [12][20]